Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
This article summarizes current health news, covering topics like potential bone loss from thyroid medication, dementia risks from wildfire smoke, and updates on pharmaceutical pricing policies. It ...
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in ...
Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Amgen (AMGN – Research Report) today. The company’s shares closed ...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...
Sen. Bernie Sanders is blaming the Democratic Party after Vice President Kamala Harris lost to now President-elect Donald Trump and Republicans gained control of the Senate. In a statement shared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback